RevitalVision reports positive trial data for infantile nystagmus

RevitalVision says a randomized study published in the British Journal of Ophthalmology found its digital therapeutic improved vision in patients with infantile nystagmus. The results point to a potential non-invasive option for a condition that has had limited treatment choices.

Why it matters: - Infantile nystagmus can reduce visual acuity, impair depth perception and make everyday tasks harder. - The condition affects about 1 in 1,000 people, and many patients have limited options to improve vision beyond optical correction. - RevitalVision’s data suggest a non-invasive digital treatment may improve both clinical vision measures and day-to-day function.

What happened: - RevitalVision announced the publication of positive clinical data for its digital therapeutic in the British Journal of Ophthalmology on May 6, 2026. - The study, titled “Efficacy of perceptual learning among patients with Infantile Nystagmus,” was conducted at Shamir Medical Center in Israel. - The trial evaluated a structured program of visual perceptual exercises designed to improve cortical visual processing. - The company said the study provides the first randomized controlled evidence that RevitalVision can improve visual function in patients with infantile nystagmus.

The details: - Patients in the trial showed statistically significant improvements in visual acuity, contrast sensitivity and functional vision. - The study also found significant gains in near and distance best-corrected visual acuity. - Forty-six percent of treated subjects reached driving-license vision of 20/40. - Significant improvements were measured in contrast sensitivity, stereoacuity and binocular vision. - Half of the study patients, 13 of 26, reported subjective improvements in both distance and near vision. - Forty-two percent, 11 of 26, said night vision improved. - 76.9% of participants, or 20 of 26, said they would recommend the treatment to others. - Dr. Sigal Zmujack-Yehiam, the lead researcher, said patient-reported outcomes showed the visual gains had an impact on daily functioning, not just clinical test results. - RevitalVision is an FDA-cleared perceptual learning software program. - The software has also been clinically validated in adult amblyopia, keratoconus, post-cataract surgery and presbyopia. - The program is prescribed by eye care specialists and delivered digitally. - Trained clinicians remotely monitor progress. - The company says the treatment uses patient-specific visual stimulation that harnesses the brain’s capacity to process vision. - To learn more about the company and science, visit more information. - The full study is available in the British Journal of Ophthalmology: the full study

Between the lines: - The study adds randomized controlled evidence to a field where infantile nystagmus has had few treatment options. - The reported gains in both objective testing and patient experience strengthen the case for perceptual learning as a practical therapy. - The results also help position RevitalVision beyond its earlier use cases in other eye conditions.

What's next: - RevitalVision is likely to use the publication to expand clinician awareness of the therapy for infantile nystagmus. - The company’s next challenge is broader adoption, including how widely eye specialists prescribe the program and how payers view the evidence. - Further studies could help define which patients benefit most and how durable the vision gains remain over time.

The bottom line: - RevitalVision now has peer-reviewed randomized data backing a digital treatment that could offer a new path for patients with infantile nystagmus.